Global Immune Checkpoint Inhibitors Market Study 2015-2025, by Segment (PD-1/PD-L1, CTLA-4), by Market (Lung Cancer, Colorectal Cancer, Breast Cancer, … …), by Company (Bristol Myer Squibb, AstraZeneca, Merck & Co., … …)

Published by 99Strategy on 6th December 2018 | Ref: 1108499 | This Report Is In Stock

$1800 | Single User
$3600 | Site License
$3600 | Enterprise License
$1800 | Single User
$3600 | Site License
$3600 | Enterprise License

Introduction

Snapshot

The global Immune Checkpoint Inhibitors market will reach xxx Million USD in 2018 and with a CAGR if xx% between 2019-2025.

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

PD-1/PD-L1

CTLA-4

Demand Coverage (Market Size & Forecast, Consumer Distribution):

Lung Cancer

Colorectal Cancer

Breast Cancer

Prostate Cancer

Melanoma

Blood Cancer

Other

Company Coverage (Sales data, Main Products & Services etc.):

Bristol Myer Squibb

AstraZeneca

Merck & Co.

Roche / Genentech

Incyte Corporation

NewLink Genetics

ArGEN-X

Seattle Genetics

Pfizer

MacroGenics

Celldex Therapeutics

CureTech

Immutep

Innate Pharma

Sorrento Therapeutics

GlaxoSmithKline

GITR, Inc

Major Region Market

North America

Europe

Asia-Pacific

South America

Middle East & Africa

Table of Contents

Table of Content

1 Industry Overview

1.1 Immune Checkpoint Inhibitors Industry

1.2 Market Segment

1.3 Price & Cost Overview

2 Immune Checkpoint Inhibitors Market by Type

2.1 By Type

2.2 Market Size by Type

2.3 Market Forecast by Type

3 Global Market Demand

3.1 Segment Overview

3.2 Market Size by Demand

3.3 Market Forecast by Demand

4 Major Region Market

4.1 Global Market Overview

4.2 Major Region

5 Major Companies List

5.1 Bristol Myer Squibb (Company Profile, Sales Data etc.)

5.2 AstraZeneca (Company Profile, Sales Data etc.)

5.3 Merck & Co. (Company Profile, Sales Data etc.)

5.4 Roche / Genentech (Company Profile, Sales Data etc.)

5.5 Incyte Corporation (Company Profile, Sales Data etc.)

5.6 NewLink Genetics (Company Profile, Sales Data etc.)

5.7 ArGEN-X (Company Profile, Sales Data etc.)

5.8 Seattle Genetics (Company Profile, Sales Data etc.)

5.9 Pfizer (Company Profile, Sales Data etc.)

5.10 MacroGenics (Company Profile, Sales Data etc.)

5.11 Celldex Therapeutics (Company Profile, Sales Data etc.)

5.12 CureTech (Company Profile, Sales Data etc.)

5.13 Immutep (Company Profile, Sales Data etc.)

5.14 Innate Pharma (Company Profile, Sales Data etc.)

5.15 Sorrento Therapeutics (Company Profile, Sales Data etc.)

5.16 GlaxoSmithKline (Company Profile, Sales Data etc.)

5.17 GITR, Inc (Company Profile, Sales Data etc.)

6 Conclusion

Additional Details

Publisher

99Strategy

Publisher Information

Reference

1108499 | 99SHea20181816846

Number of Pages

58

Report Format

PDF

This report is published by 99Strategy

Download Free Report Summary PDF

Global Immune Checkpoint Inhibitors Market Study 2015-2025, by Segment (PD-1/PD-L1, CTLA-4), by Market (Lung Cancer, Colorectal Cancer, Breast Cancer, … …), by Company (Bristol Myer Squibb, AstraZeneca, Merck & Co., … …) [Updated: 06-12-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.